Implantable device for controlled dissolution and diffusion of low solubility drug

Patent metadata

Field	Value
Publication number	US-9107816-B2
Application number	US-201213366981-A
Country	US
Kind code	B2
Filing date	Feb 6, 2012
Priority date	Feb 4, 2011
Publication date	Aug 18, 2015
Grant date	Aug 18, 2015

Abstract

Implantable drug delivery devices are provided that are deformable between a relatively straightened shape suitable for deployment and a retention shape suited to retain the device within the bladder or other body cavity. While in the body cavity, the devices release drug from solid drug units housed in the devices. The devices are designed to house the solid drug units in a way that exposes one or more sides of the solid drug units to the fluid at the in vivo site of deployment. Methods for using the devices for administering drug and making the devices also are provided.

First claim

We claim:

1. An implantable drug delivery device comprising:
a drug housing portion which comprises
at least one solid drug unit comprising a drug, and
at least one housing having at least one defined opening, wherein the at least one solid drug unit is located within the defined opening such that the housing encases a first portion of the surface of the at least one solid drug unit and exposes a second portion of the surface of the at least one solid drug unit,

wherein the device is elastically deformable between a relatively straightened shape suited for insertion through a lumen into a body cavity of a patient and a retention shape suited to retain the device within the body cavity, and
wherein release of the drug from the device is controlled by erosion of the exposed second portion of the surface of the at least one solid drug unit.

2. The device of claim 1 , wherein the at least one solid drug unit is a tablet which comprise a low solubility drug.

3. The device of claim 1 , wherein the drug comprises gemcitabine, docetaxel, carboplatin, cisplatin, trospium, tolterodine, mitomycin C, or a combination thereof.

4. The device of claim 1 , wherein the rate of the release of the drug from the drug delivery device is zero order over at least 24 hours.

5. An implantable drug delivery device comprising:
a drug housing portion which comprises
at least two solid drug units, and
at least one housing encasing a first portion of the surface of each solid drug unit, and having at least two defined openings that expose a second portion of the surface of each solid drug unit,

wherein the device is elastically deformable between a relatively straightened shape suited for insertion through a lumen into a body cavity of a patient and a retention shape suited to retain the device within the body cavity, and
wherein release of the drug from the device is controlled by erosion of the exposed second portion of the surface of the solid drug units,
wherein the at least one housing is configured to expose a constant surface area of the at least two solid drug units at the at least two defined openings as the at least two solid drug units are dissolved at the exposed surface area.

6. The drug delivery device of claim 5 , wherein the at least one housing comprises at least three defined openings so that a third portion of the surface of at least one solid drug unit is exposed.

7. The drug delivery device of claim 5 , wherein the at least one housing comprises at least four defined openings so that a third portion of the surface of each solid drug unit is exposed.

8. The drug delivery device of claim 5 , wherein the solid drug unit comprises a low solubility drug.

9. The drug delivery device of claim 5 , wherein the at least one housing comprises a flexible elongated monolithic structure having a longitudinal axis and a plurality of separate drug reservoir lumens oriented substantially perpendicularly to the longitudinal axis.

10. The drug delivery device of claim 9 , wherein the at least one housing further comprises a retention frame lumen oriented substantially parallel to the longitudinal axis.

11. The drug delivery device of claim 5 , wherein the at least one housing comprises two or more modular housing units.

12. The drug delivery device of claim 11 , wherein the two or more modular housing units each comprise:
(i) a drug reservoir lumen housing at least one of the solid drug units, and
(ii) at least one retention frame lumen, the plurality of modular housing units having a shared retention frame extending through the retention frame lumens.

13. The drug delivery device of claim 12 , wherein the drug reservoir lumen has two opposed openings which expose correspondingly opposed end surfaces of the at least one solid drug units housed therein.

14. The drug delivery device of claim 12 , wherein the drug reservoir lumen is oriented substantially parallel to the retention frame lumen.

15. The drug delivery device of claim 12 , wherein the drug reservoir lumen is oriented substantially perpendicular to the retention frame lumen.

16. The drug delivery device of claim 5 , further comprising a retention frame.

17. The drug delivery device of claim 16 , wherein the retention frame comprises a superelastic alloy wire or strip.

18. The drug delivery device of claim 5 , wherein the at least two solid drug units comprise gemcitabine, docetaxel, carboplatin, cisplatin, trospium, tolterodine, mitomycin C, or a combination thereof.

Assignees

• Lee Heejin
• Duc Hong Linh Ho
• Sansone Matthew
• Taris Biomedical Llc

Inventors

• Lee Heejin
• Duc Hong Linh Ho
• Sansone Matthew

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P13/10

  of the bladder · CPC title

• A61K31/46

  8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine · CPC title

• A61K31/7064

  containing condensed or non-condensed pyrimidines · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title